Recent trends indicate the GLP-1 market will exceed $100 billion by 2030; this is not a surprise for the health care system as discussion and use of these medications within this class has continued to soar. As the prescribing of these medications continue to increase, pharmacists in all settings must be well versed to ensure they are able to provide appropriate counseling, education, and adjustments for patients and provide clinical insight to the healthcare team.
REFERENCES/RESOURCES
- ADA Standards of Care 2024 - Volume 47 Issue Supplement_1 | Diabetes Care | American Diabetes Association (diabetesjournals.org)
- Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity | FDA
- GLP-1 Receptor Agonists and the Risk of Thyroid Cancer - PubMed (nih.gov)
- Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials - PubMed (nih.gov)
- Incretin-Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes - PubMed (nih.gov)
- Use of DPP4 Inhibitors and GLP-1 Receptor Agonists and Risk of Intestinal Obstruction: Scandinavian Cohort Study - PubMed (nih.gov)
- HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression - PubMed (nih.gov)
Jessica Boh, PharmD, MPH, BCPS, BCACP, (she/her) earned her PharmD from the University of Florida and Master of Public Health from Florida International University. She completed a PGY1 at the Memphis VA Medical Center and a PGY2 in Ambulatory Care at the North Chicago VA/DoD. Dr. Boh is currently a clinical pharmacist practitioner at the Washington DC VA, integrated into the Primary Care team to manage a variety of chronic disease states including diabetes, hypertension, hyperlipidemia, and weight management. 
Megan Adelman, PharmD, BCPS, BCGP, CDCES, (she/her) is a family medicine pharmacy specialist at the Cleveland Clinic Akron General Center for Family Medicine. She earned her PharmD from the Northeast Ohio Medical University and completed her postgraduate year 1 pharmacy residency at the Carolinas Medical Center and a postgraduate year 2 residency in geriatrics at the Louis Stokes Cleveland VAMC. Adelman has worked to expand pharmacy services, helping to implement multiple interdisciplinary clinics. 
Paris Smith, PharmD, BCACP, (she/her/hers) is an ambulatory pharmacist with Parkview Health in Fort Wayne, Indiana. She provides direct patient care for anticoagulation, diabetes, and cardiovascular risk reduction. She graduated from SIUE School of Pharmacy in Edwardsville, IL and then went to complete her PGY-1 residency with Lovell FHCC in North Chicago, IL and her PGY-2 in ambulatory care/academia with Pacific University in Hillsboro, OR. Her current practice interests include diabetes, anticoagulation, mental health, asthma and COPD. 
